Beryllium Compliance Plan
Written compliance plan for beryllium exposure under the updated 2017/2020 OSHA standards. PEL 0.2 µg/m³ TWA; STEL 2.0 µg/m³; Action Level 0.1 µg/m³. Covers Chronic Beryllium Disease (CBD) prevention, BeLPT medical surveillance, and the regulated area controls.
When this template is required
Required wherever beryllium exposure occurs. PEL: 0.2 µg/m³ 8-hour TWA; STEL: 2.0 µg/m³ 15-min; Action Level: 0.1 µg/m³. The current OSHA beryllium standards were promulgated in 2017 and updated in 2020 — substantially stricter than the previous 2 µg/m³ PEL. Beryllium causes Chronic Beryllium Disease (CBD), a serious lung disease, plus lung cancer.
Why this template
Updated 2017/2020 standards
OSHA's updated beryllium standards reduced the PEL by a factor of 10 (from 2 µg/m³ to 0.2 µg/m³). Many facilities have not fully updated their compliance programs to the new requirements. The plan reflects the current standards.
Three parallel standards
General industry (1910.1024), construction (1926.1124), and shipyard (1915.1024) have parallel beryllium standards. The plan covers all three with crosswalk.
BeLPT medical surveillance
Beryllium-Lymphocyte Proliferation Test detects beryllium sensitisation BEFORE Chronic Beryllium Disease develops. Sensitised workers can develop CBD over years — early identification allows medical management and exposure reduction.
Dermal exposure route
Beryllium is unusual among OSHA-regulated substances in causing sensitisation via skin exposure (not just inhalation). The plan addresses skin exposure controls — gloves, work clothing, hygiene. Dermal contact duties sit in the general industry standard (1910.1024); the construction and shipyard standards do not carry them.
What you receive
- Beryllium Compliance Plan (Word .docx) — written program per (d)-(n)
- Initial exposure determination procedure (PEL: 0.2 µg/m³ TWA / 2.0 µg/m³ STEL; Action Level: 0.1 µg/m³)
- Air monitoring schedule (initial + periodic + change-triggered)
- Methods of compliance — engineering & work practice controls hierarchy
- Respiratory protection program crosswalk (with 1910.134)
- Medical surveillance protocol (PLHCP examination, blood/biological tests as applicable)
- Beryllium work area and regulated area designation procedure (work areas per the Appendix A criteria; regulated areas above the TWA PEL or STEL — general industry and shipyards)
- Housekeeping and hygiene procedures
- Employee training outline (annual refresher requirement)
- Recordkeeping requirements (exposure: 30 years; medical: employment + 30 years)
- Beryllium-Lymphocyte Proliferation Test (BeLPT) medical surveillance protocol
- CBD case management procedure
- Skin exposure controls (dermal sensitisation route)
- Welding/machining of beryllium-copper alloys trigger procedure
How you get it
This document is written and reviewed against the standard it cites, and it is ready now. The download link is emailed as soon as your payment clears.
Revisions included — if something about your operation changes what the document should say, reply to the delivery email and we will amend it.
Who buys this
- Beryllium primary production and processing
- Beryllium-copper alloy machining and fabrication
- Aerospace and defense manufacturing (beryllium components)
- Electronics and semiconductor (beryllium oxide substrates)
- Foundries casting beryllium alloys
- Dental laboratories (beryllium-containing dental alloys)
- Welding/brazing on beryllium-containing materials
Frequently asked
What changed in OSHA's 2017/2020 beryllium standards?
OSHA promulgated three new beryllium standards in 2017 (1910.1024 general industry, 1926.1124 construction, 1915.1024 shipyard), with technical amendments in 2020. The PEL dropped from 2 µg/m³ to 0.2 µg/m³ (factor of 10). Action Level: 0.1 µg/m³. New STEL: 2.0 µg/m³ 15-min. Medical surveillance including the BeLPT is required for employees exposed at or above the action level for more than 30 days a year, and on the other 1910.1024(k)(1)(i) triggers. The three standards are not identical: dermal contact duties appear only in the general industry standard, and regulated areas above the TWA PEL or STEL are required under general industry (1910.1024(e)(1)(ii)) and shipyards (1915.1024(e)) — the construction standard contains no regulated area provision at all.
What's Chronic Beryllium Disease (CBD)?
CBD is a granulomatous lung disease caused by beryllium sensitisation followed by exposure. The disease can progress over years and is sometimes mistaken for sarcoidosis. CBD can be debilitating and is sometimes fatal. The BeLPT identifies sensitised individuals BEFORE CBD develops; removal from exposure and medical management slow or prevent progression.
What's BeLPT?
Beryllium-Lymphocyte Proliferation Test — a blood test that detects beryllium sensitisation. Lymphocytes from exposed individuals proliferate when exposed to beryllium salts in vitro; non-exposed individuals show no proliferation. A single abnormal BeLPT is not by itself a finding of sensitisation. 1910.1024(b) defines a "confirmed positive" as two abnormal results, one abnormal and one borderline, or three borderline results obtained within a three-year period. Under 1910.1024(k) the BeLPT is offered at the initial examination and at least every two years thereafter, and it is a confirmed positive — or a CBD diagnosis — that leads to referral to a CBD diagnostic centre and the medical removal provisions of 1910.1024(l).
What about beryllium-copper alloys?
Beryllium-copper alloys (typically 1-2% beryllium) are widely used in connectors, springs, tooling, and aerospace. Machining, welding, brazing, or grinding beryllium-copper generates beryllium-containing dust/fume. Even at 2% beryllium, the air concentrations can exceed the AL. The plan covers beryllium-copper as a primary use case.
Are dental labs affected?
Yes — certain dental alloys contain beryllium for casting characteristics. Dental lab technicians casting, polishing, or finishing these alloys can have measurable beryllium exposure. The 2017 standard expanded enforcement to dental labs and small operations. The plan addresses dental lab scenarios.